# GLP-1 vs SGLT2 Inhibitor: What the Heart Outcome Evidence Shows | Buy This GLP

Compare GLP-1 and SGLT2 inhibitor evidence for people with type 2 diabetes and a prior heart attack, and see what current guidance considers.

Publisher: Buy This GLP Editorial Team
Canonical: https://buythisglp.com/research/which-is-better-a-glp1-or-an-sglt2-inhibitor
Updated: 2026-11-15
Published: 2026-09-17

[← Research](https://buythisglp.com/research)

Evidence

# GLP-1 vs SGLT2 Inhibitor: What the Heart Outcome Evidence Shows

Both drug classes reduced major cardiovascular events versus placebo in a review of people with diabetes and a prior heart attack. The class comparison was indirect.

Editorial profile: [Wesley Jenkins](https://buythisglp.com/authors/wesley-jenkins)[Buy This GLP Editorial Team](https://buythisglp.com/about)September 20264 min readUpdated November 2026

SGLT2 inhibitor against GLP-1 — all of it indirect · major CV events · 7 studies: 2 vs 5 · heart failure admission · 6 studies: 2 vs 4 · heart attack · 4 studies: 1 vs 3 · These estimates come from separate placebo trials.

**Research, not medical advice.** Buy This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://buythisglp.com/methodology) and [terms](https://buythisglp.com/terms).

## Key takeaways

-   Both classes lowered major cardiovascular events versus placebo in a review of people with type 2 diabetes and a prior heart attack.
-   The comparison between classes was indirect and did not establish a clear difference.
-   Current guidance weighs the person’s heart, kidney and metabolic conditions when choosing a drug.

The best choice depends on the reason for treatment and the evidence for the specific medicine. Studies of [GLP-1 drugs and heart attacks](https://buythisglp.com/research/do-glp1-drugs-prevent-heart-attacks) include several different populations. This review focused on people with type 2 diabetes and a history of heart attack [\[1\]](https://buythisglp.com/research/which-is-better-a-glp1-or-an-sglt2-inhibitor#ref-1).

## What the comparison found

Against placebo, the hazard ratio for major cardiovascular events was 0.87 for SGLT2 inhibitors and 0.83 for GLP-1 drugs. The indirect comparison of SGLT2 inhibitors with GLP-1s gave 1.05 (95% CI 0.92 to 1.20) [\[1\]](https://buythisglp.com/research/which-is-better-a-glp1-or-an-sglt2-inhibitor#ref-1). It did not establish a clear advantage for either class.

For heart failure admission, the indirect hazard ratio was 0.83 (95% CI 0.67 to 1.03). The estimate favored SGLT2 inhibitors, but the interval included no difference. Most studies included people whose heart attacks occurred well before enrollment. The findings are less directly applicable immediately after a heart attack.

## How clinicians choose between the classes

The 2026 ADA and EASD consensus uses a person’s cardiovascular and kidney risk to guide treatment [\[2\]](https://buythisglp.com/research/which-is-better-a-glp1-or-an-sglt2-inhibitor#ref-2). Our guide to [taking a GLP-1 and an SGLT2 inhibitor together](https://buythisglp.com/research/can-you-take-a-glp1-and-an-sglt2-inhibitor-together) covers a third option clinicians may consider. The indirect class comparison above estimates outcomes for each class separately.

Heart failure, chronic kidney disease, weight goals and tolerability all affect that choice.

## Frequently asked

Was the comparison between classes direct?

The review estimated the difference through separate placebo-controlled trials.

Did one class clearly reduce major cardiovascular events more?

The indirect hazard ratio was 1.05, with a 95% confidence interval of 0.92 to 1.20. It leaves uncertainty about which class had the larger benefit.

What factors guide the choice?

A clinician considers the reason for treatment, including heart failure, kidney disease, cardiovascular risk and weight-related goals.

## Sources

1.  \[1\] Ren Y, et al. (2026). Cardiovascular outcomes of SGLT2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes and a history of myocardial infarction Frontiers in Endocrinology. [PMID 42591121](https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2026.1902802/full)
2.  \[2\] American Diabetes Association and European Association for the Study of Diabetes (2026). Management of type 2 diabetes, 2026: a consensus report Diabetologia. [Source](https://link.springer.com/article/10.1007/s00125-026-06855-7)

## Where to get it

### Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

[Open the price desk →](https://buythisglp.com/)

## More in Evidence

-   [
    
    50,678 adults with a BMI of 30 or more · Prescribed · 8.0% · Filled · 4.4% · Outlined bar runs to 10%. Medicaid had lower odds of both.
    
    ### Does Medicaid Cover Weight Loss Drugs? It Depends on Your State
    
    ](https://buythisglp.com/research/does-medicaid-cover-weight-loss-drugs)
-   [
    
    What the claim rests on · Sleep study · AHI 15 or more · Obesity · BMI 30 or more · Prescription · for sleep apnea · Part D claim · plan review · Trial thresholds shown. Your plan sets its approval requirements.
    
    ### Does Medicare Cover Zepbound for Sleep Apnea? The Diagnosis Is the Key
    
    ](https://buythisglp.com/research/does-medicare-cover-zepbound-for-sleep-apnea)
-   [
    
    Illustrative decline with a one-week half-life · Ozempic window: up to 5 days late · 100% · day 0 · 82% · day 2 · 67% · day 4 · 61% · day 5 · 50% · day 7 · A calculation from the label half-life, not a blood test.
    
    ### What Happens If You Miss a Dose of Ozempic? A Week-Long Half-Life Buys Time
    
    ](https://buythisglp.com/research/what-happens-if-you-miss-a-dose-of-ozempic)
